SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description

   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


National Association for Continuing Education


Course Directors
Gregg Sherman, MD
Chief Medical Officer, NACE
Plantation, FL

Deborah Paschal, CRNP
Philadelphia, PA

Medical Writer
Josh Kilbridge
Kilbride Associates Healthcare Communications
San Francisco, CA

Course Reviewer
Alexander Duarte, MD
Professor
Division of Pulmonary Critical Care & Sleep Medicine
Department of Internal Medicine
University of Texas Medical Branch
Galveston, TX

Title
: Clinical Advances in Pulmonary Arterial Hypertension
Activity/Course #:
: NCME346
Cost:
: Free
Release/Start Date:
: Jan 15 2018
Expiration Date:
: Jan 14 2019
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Providers
Format:
: Monograph
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes .25 pharmacology hour(s)
Hardware/Software Requirements:

Welcome to the National Association for Continuing Education monograph from the NACE Clinical Updates for NPs and PAs 2017 conference.

Pulmonary arterial hypertension (PAH) is a subgroup of pulmonary hypertension (PH) - a chronic and progressive condition characterized by abnormally high pressure in the pulmonary vasculature. PAH has previously been considered a rare disease, but evidence suggests a prevalence of about 15-50 cases per million. In the United States, about 1,000 new cases of PAH are diagnosed each year while mortality and hospitalization rates for PH have been increasing. 
 
Dyspnea with exertion is by far the most common presenting symptom of PAH, but this symptom is often mistakenly attributed to other causes such as deconditioning, obesity, asthma, or other known underlying pulmonary or cardiac disorders. In practice, early recognition of PAH remains a challenge because the condition does not become clinically manifest until pulmonary vascular disease is advanced. Expertise in the diagnosis and management of PAH is uncommon, and PAH is underdiagnosed and misdiagnosed.
 
Dramatic advances in the treatment of PAH have occurred over the past two decades, as demonstrated in multiple studies. Despite these advances, education and training of clinicians has lagged behind advances in the management of PAH.
 
This monograph will help primary care clinicians develop a greater awareness and comfort level with the identification, diagnosis and management of patients with PAH.

Learning Objective(s):

After completing this program participants should be able to:

  1. Discuss the pathophysiology of pulmonary arterial hypertension (PAH)
  2. Recognize signs and symptoms suggestive of PAH and the appropriate diagnostic strategy
  3. Describe how to monitor patients with PAH for disease progression
  4. Review current and emerging treatments for patients with PAH

How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 70% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hours of continuing education (which includes 0.25 pharmacology hours).
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Alexander Duarte, MD, Course Reviewer, has no relationships to disclose.

Gregg Sherman, MD, Course Director, has no relationships to disclose.

Josh Kilbridge, Medical Writer, has no relationships to disclose.

Harvey C. Parker, Ph.D., Activity Planning Committee, has no relationships to disclose.

Michelle Frisch, MPH, Activity Planning Committee, has no relationships to disclose.
Commercial Support
This educational activity is supported by an an educational grant from Actelion Pharmaceuticals US, Inc.